Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study

What Was Tested

Researchers studied Tirzepatide in the context of atherosclerosis, cardiovascular disease & high blood pressure in this observational study publication.

Who Took Part

According to the abstract, 52,971 participants were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

52 971 participants aged ≥40 years with type 2 diabetes and established atherosclerotic cardiovascular disease who initiated tirzepatide (n=35 353) or sitagliptin (n=17 618), a cardiovascular outcome neutral comparator serving as a placebo proxy.

Baseline characteristics were well balanced between treatment groups after propensity score overlap weighting.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Population based cohort study, using a design, data, and analytical approach previously benchmarked against randomised trials.

Two national US claims databases, May 2022 to May 2025.

What Was Measured

PubMed files the paper under topics including Atherosclerosis, Cardiovascular Diseases, Cohort Studies, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents and Myocardial Infarction.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide in 52,971 participants in people with atherosclerosis, cardiovascular disease & high blood pressure.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (BMJ (Clinical research ed.)), a journal based in England.

More context: the Tirzepatide compound page, Atherosclerosis, cardiovascular disease & high blood pressure research.